ArticleEJNMMI research2018
Synthesis and preclinical evaluation of novel
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Repeatability of QuantitativeJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- In vivo stableEJNMMI radiopharmacy and chemistry · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Development of the FirstPharmaceutics · 2023Article
- Comparative study ofFrontiers in medicine · 2023Article
- Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.European journal of nuclear medicine and molecular imaging · 2022Article
- Diagnostic value of integratedProstate international · 2022Article
- PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.International journal of molecular sciences · 2022Review
- Synthesis and Preclinical Evaluation of aJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?EJNMMI radiopharmacy and chemistry · 2021Article
- Preclinical comparison of four [EJNMMI research · 2020Article
- Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation ofChemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.Prostate cancer and prostatic diseases · 2020Article
- "Luke! Luke! Don't! It's a trap!"-spotlight on bias in animal experiments in nuclear oncology.European journal of nuclear medicine and molecular imaging · 2020Article
- Radiohybrid Ligands: A Novel Tracer Concept Exemplified byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Review
- Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.Science advances · 2019Article
- Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity.EJNMMI research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDue to its high and consistent expression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) represents an ideal target for molecular imaging and targeted therapy using highly specific radiolabeled PSMA ligands. To address the continuously growing clinical demand for
resultsRadiolabeling procedures allowed preparation of (1) and (2) with high radiochemical yields (67 ± 7 and 53 ± 7%, d.c.) and purity (> 98%). When compared with
conclusionBoth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.